Company intelligence / Profile preview
Shanghai Vitalgen BioPharma Co., Ltd.
Shanghai, Shanghai, Chinavitalgen.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
The company has multiple programs in clinical development, with the most advanced being in Phase 3 (VGN-R09b for Aromatic Amino Acid Decarboxylase Deficiency and VGR-R01 for Bietti Crystalline Dystrophy). Their VGB-Ex01 for Beta Thalassaemia is in Phase 2 with a 38% phase transition success rate for progressing to Phase 3.
- Therapeutic areas
- Metabolic DisordersOncologyRare DiseasesHematologyOphthalmology
- Modalities
- AAV-based gene therapyGene editingCell therapyLipid nanoparticle delivery
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →03
Partnerships
Novoprotein
Beyond the preview
Go deeper on Shanghai Vitalgen BioPharma Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Vitalgen BioPharma Co., Ltd..